EGFR and non-small cell lung carcinoma: The introduction of first- or second-generation epidermal growth factor receptor gene (EGFR) tyrosine kinase inhibitors (TKIs) in chemonaive patients with advanced non-small cell lung cancer (NSCLC) has radically changed the treatment in this molecular subgroup, with an improvement in progression-free survival (PFS) compared to standard chemotherapy[1].